57 results about "Nasal polyps" patented technology

Methods of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject, methods of treating chronic rhinosinusitis (CRS) or chronic rhinosinusitis with nasal polyps (CRSwNP) in a human subject, methods of treating a eustachian tube disorder in a human subject, and devices and systems for performing the methods. A method of treating a central airway obstruction (CAO), benign airway stenosis, asthma, chronic obstructive pulmonary disease (COPD), or an airway tumor in a human subject includes inserting a drug-coated balloon catheter into a target site in a trachea, mainstem bronchus, bronchus intermedius, lobar bronchus, segmental bronchus, or sub-segmental bronchus, wherein the balloon is coated with a coating layer including the therapeutic agent and one or more additives. The therapeutic agent includes paclitaxel, sirolimus, or a derivative thereof. The method includes inflating the balloon to dilate the airway and deliver a therapeutic agent to the airway wall. The method includes deflating the balloon. The method also includes withdrawing the balloon catheter from the target site.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

The invention discloses application of a TGM2 inhibitor in treatment of chronic sinusitis with nasal polyp, asthma and fibrosis complications thereof. Through single cell transcriptome analysis, it is found that the TGM2 is specifically and highly expressed in a macrophage subset (Tgm < 2 + > macrophage) in a CRSwNP sample with asthma, and the TGM2 protein expression level is significantly and positively correlated with the clinical severity of diseases such as CRSwNP and asthma; animal experiments verify that pathological injuries of the nasal cavity and the lung of a Tgm2-knocked-out mouse type 2 inflammation model are relieved, the inflammation of the upper and lower respiratory tracts of the mouse and the fibrosis level of the lung tissue can be remarkably relieved by adopting a small molecule drug ERW1041E for nasal drop administration, and the safety is good; the invention provides a brand-new treatment strategy for patients with diseases related to type 2 inflammation, and has remarkable clinical transformation value and market prospect.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Provided herein are methods and uses of antibodies that specifically bind human IL-13 ("anti-IL-13 antibodies") for the treatment of chronic rhinosinusitis with nasal polyps.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine composition for treating rhinitis based on a fructus xanthii extract and a preparation method of the traditional Chinese medicine composition. 5%-7% of liquorice; 15%-20% of dark plum; 2%-5% of bighead atractylodes rhizome; 20%-25% of schisandra chinensis; 1%-3% of almonds; 5%-8% of cortex mori radicis; 4%-11% of centipeda minima; 4%-7% of fructus chebulae; 0.2%-0.5% of cassia twig; 1%-3% of radix saposhnikoviae and 4%-9% of 4%-7% of radix astragali; 3%-6% of radix ophiopogonis; the raw materials are processed and proportioned, and the traditional Chinese medicine ointment is prepared through the processes of decoction of the detoxifying and synergistic group, concentration of the orifice-opening and exterior-strengthening group, extraction of the qi-tonifying and yin-nourishing group, mixed light decoction and concentration. When the ointment is used, a cotton swab is coated with the ointment, the cotton swab coated with the ointment is fed into the nasal polyp part of a rhinitis patient and stays for about 20 minutes, after the drug effect of the ointment is slowly released, the nasal polyp necroses, part of the nasal polyp can fall off after about 15 days, and the treatment process can be repeated for multiple times and once every 15 days until the nasal polyp completely falls off. The ointment can effectively relieve nasal obstruction, running nose, rhinocnesmus and sneezing symptoms of rhinitis patients; the traditional Chinese medicine is not required to take medicine but is only externally used, is very safe to use and has no toxic or side effect.

The present invention discloses a composition for improving rhinitis symptoms and nasal cleaning, as well as its preparation method and application. The composition comprises, by weight, 0.1 to 7 parts of yeast β-glucan and 0.1 to 6 parts of mussel mucin. The present invention prepares a composition for improving rhinitis symptoms and nasal cleaning by rationally combining ultra-low molecular weight yeast β-glucan, low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, and mussel mucin. The composition can be effectively used for nasal cleaning of patients with nasal diseases such as acute rhinitis, chronic rhinitis, allergic rhinitis, nasal polyps, sinusitis, etc., and can also be used for nasal cleaning after nasal tumor surgery or chemotherapy.

The invention belongs to the technical field of medicine, and discloses a medicinal sponge sheet for inhibiting growth of nasal polyp, the medicinal sponge sheet is composed of a medical grade absorptive gelatin sponge base material, triamcinolone acetonide and hydroxypropyl methyl cellulose, the medicinal sponge sheet adopts the medical gelatin base material with the porosity of 95% and the water absorption expansion rate of less than or equal to 30%, the size is 60mm * 20mm * 5mm, each sheet loads 60mg of triamcinolone acetonide, and the hydroxypropyl methyl cellulose is added into the medicinal sponge sheet. And 10% of hydroxypropyl methyl cellulose with the molecular weight of 35000 Da and the viscosity of 700 mPa.s is supplemented to construct a slow release system. Efficient and safe treatment of chronic nasosinusitis with nasal polyp is achieved through multi-dimensional innovative design, the three-dimensional interpenetrating pore structure of the medical gelatin base material provides an ideal carrier for drug release, 60%-70% of triamcinolone acetonide is continuously released within 7 days through the gradient slow release technology, a local high-concentration microenvironment is constructed, and the effect of treating chronic nasosinusitis with nasal polyp is achieved. The device directly acts on the polyp root to block an inflammation cascade reaction; in the formula, hydroxypropyl methyl cellulose is used as a core slow-release carrier.

The invention provides a budesonide temperature-sensitive gel preparation as well as a preparation method and application thereof, and the budesonide temperature-sensitive gel preparation is mainly prepared from the following components: budesonide, poloxamer 407, poloxamer 188, propylene glycol, hydroxypropyl methyl cellulose, sodium benzoate and pure water. After the budesonide temperature-sensitive gel drug delivery system based on poloxamer 407, poloxamer 188 and hydroxypropyl methylcellulose is applied to a cavity, semi-solid gel can be quickly formed, and strong retention and slow release effects are shown, so that the bioavailability is increased, the formed semi-solid gel can be retained at a drug delivery part and cannot be lost, and the budesonide temperature-sensitive gel drug delivery system is suitable for clinical application. In addition, budesonide can be gradually released, and a remarkable curative effect is shown in short-term clinical application of recurrent chronic sinusitis with nasal polyp.

Methods for treating or preventing chronic rhinosinusitis without nasal polyps (CRSsNP) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The application discloses application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating chronic rhinosinusitis with nasal polyps. The medicine preparation is composed of an effective amount of the CGRP receptor small molecule antagonist and pharmaceutically acceptable adjuvants, and the dosage form is a nasal spray / drop / irrigation agent, and the administration route is simple and easy to operate, and is convenient for patients to use. The application can significantly reduce eosinophilic inflammation by inhibiting CGRP-mediated mast cell activation, and has a clear treatment advantage for eosinophilic nasal polyps. Compared with a biological preparation targeting type 2 cytokines, a small molecule compound is safer and simpler to obtain, can significantly reduce the treatment cost of patients, and provides a new efficient and economical choice for nasal polyp treatment.

The present disclosure relates generally to methods of treating chronic sinusitis with or without nasal polyp using antibodies specific for thymic stromal lymphopoietin (TSLP).

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

This disclosure provides a method, device, and storage medium for identifying the spatial aggregation features of immune cells in nasal polyps, relating to the field of data processing technology. The implementation scheme is as follows: A nasal polyp pathological slide is segmented into multiple pathological sub-images; positive immune cells are identified in each pathological sub-image to obtain the sub-image coordinates of each positive immune cell in each pathological sub-image; based on the positional information of each pathological sub-image on the nasal polyp pathological slide, the sub-image coordinates of each positive immune cell in each pathological sub-image are mapped onto the nasal polyp pathological slide to obtain the full-map coordinates of each positive immune cell in the nasal polyp pathological slide; based on the full-map coordinates of each positive immune cell in the nasal polyp pathological slide, cluster analysis is performed on the positive immune cells in the nasal polyp pathological slide to obtain the spatial aggregation features of immune cells in the nasal polyp tissue in the nasal polyp pathological slide. This improves the accuracy of the spatial aggregation features of immune cells in nasal polyps.

Disclosed herein are antigen binding proteins, e.g. an antibody, which bind to IL-5, for use in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), wherein the nasal polyps score and / or mean nasal obstruction score is improved.

A set of antisense oligonucleotides specifically inhibiting thymic stromal lymphopoietin and the use thereof. The antisense oligonucleotide molecules have a length of 16-20 bases. The antisense oligonucleotide molecules have the following use: (1) in the preparation of a preparation for inhibiting the expression level of thymic stromal lymphopoietin; or (2) in the treatment of asthma, atopic dermatitis, chronic obstructive pulmonary disease, sinusitis, and nasal polyps.

A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg / mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.

The invention provides a nasal polyp pathological section image recognition method and device, electronic equipment and a storage medium, and relates to the technical field of artificial intelligence and data processing. According to the implementation scheme, a domain generalization model is adopted to perform domain generalization on a nasal polyp pathological section image under a first visual field of a first detection object, and a nasal polyp pathological domain invariant feature map is obtained; a cell classification model and a tissue region segmentation model are adopted to carry out cell category classification and tissue region segmentation on the nasal polyp pathological domain invariant feature map to obtain the cell type of each cell in the nasal polyp pathological domain invariant feature map, an epithelial region, a blood vessel region and a gland region, and statistics is carried out according to the cell type, the epithelial region, the blood vessel region and the gland region. And determining the nasal polyp inflammation type of the first detection object according to a statistical result. Therefore, the recognition generalization and accuracy of the nasal polyp inflammation type are improved.

The invention discloses application of tiotropium bromide serving as a medicine for treating eosinophilic nasal polyp. The application comprises application of tiotropium bromide serving as a medicine for treating nasosinusitis with nasal polyp. The invention finds that tiotropium bromide can significantly improve the epithelium remodeling condition of eosinophilic sinusitis with nasal polyp, and can solve the problem of poor effect of treating eosinophilic sinusitis with nasal polyp aiming at T2 type inflammation at present in a manner of treating eosinophilic sinusitis with nasal polyp in a non-inflammatory way.

Provided are combination dosing regimens comprising administering a monoclonal antibody, such as dupilumab, and hyaluronidase. Combinations and compositions containing the monoclonal antibody and hyaluronidase are provided. The dosing regimens and combinations with dupilumab are for treating or preventing allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis, eosinophilic esophagitis, and prurigo nodularis.

The invention relates to a traditional Chinese medicine composition for treating rhinitis and belongs to the technical field of traditional Chinese medicines. The composition is prepared from traditional Chinese medicinal materials such as centipeda minima, phryma leptostachya, cocklebur fruit, mint, asarum, camphor and the like through gradient crushing to obtain micron-sized powder with D90 smaller than or equal to 150 microns, and is prepared through low-temperature drying, volatile oil directional extraction and honey shaping processes. Aiming at acute and chronic rhinitis, allergic rhinitis, nasosinusitis, nasal polyp and other diseases, the composition provided by the invention realizes simultaneous treatment of principal and subordinate symptoms through anti-inflammatory and detumescence, immunity regulation, mucous membrane repair and other multi-target effects. According to the technology, through component optimization, process innovation and intelligent drug delivery design, the problems that a traditional Chinese medicine preparation is fuzzy in component, low in absorption rate, high in recurrence rate and the like are solved, and a safe, efficient and convenient new choice is provided for rhinitis treatment.

The present disclosure relates to antigen binding compositions, including antibodies, and related methods for treating interleukin 5 (IL-5) mediated diseases. IL-5 is a secreted protein. IL-5 plays a role in a variety of different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, sub-eosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, nasal polyposis, bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis, and severe atopic dermatitis. The disclosed compositions are suitable for treating these severe IL-5 mediated diseases.

The invention discloses a traditional Chinese medicine composition for treating rhinitis and a preparation method thereof. The traditional Chinese medicine composition comprises traditional Chinese medicine raw materials and functional auxiliary materials, wherein the traditional Chinese medicine raw materials comprise the following medicinal materials in percentage by weight: 12% of biond magnolia flower, 12% of small centipeda herb, 15% of dwarf lilyturf tuber, 3% of wild chrysanthemum flower, 3% of dahurian angelica root, 3% of dandelion, 3% of manchurian wildginger, 3% of cocklebur fruit, 8% of common burreed rhizome, 8% of curcuma zedoary, 10% of red-rooted salvia root, 6% of szechuan lovage rhizome and 6% of thunberg fritillary bulb; the functional auxiliary materials comprise the following raw materials in percentage by weight: 0.4% of cellulase, 0.2% of pectinase, 1.2% of carbomer, 0.8% of poloxamer, 0.1% of glycyrrhetinic acid, 0.05% of limonene, 5.24% of chitosan-sodium alginate and 0.01% of an anti-VEGF antibody. According to the application, a nasal polyp targeting component is added, so that the dual effects of dredging orifices, resisting inflammation (rhinitis) and resisting fiber (nasal polyp) are realized; the clinical value is higher than that of single rhinitis treatment; plant cell walls are destroyed by adopting composite enzymolysis, and fat-soluble, water-soluble and volatile oil active ingredients are synchronously extracted in combination with supercritical CO2 extraction; the mucous membrane stimulation risk caused by impurities is reduced.

This invention relates to a group of antisense oligonucleotides that specifically inhibit thymic stromal lymphopoietin and their applications. The antisense oligonucleotide molecules are 16-20 bases in length. This invention also relates to the following applications of the antisense oligonucleotide molecules (ASO): (1) preparing preparations that inhibit the expression of thymic stromal lymphopoietin; (2) treating asthma, atopic dermatitis, COPD, sinusitis and nasal polyps.

The invention provides a nasal polyp automatic grading model training method, a scoring method, a system and equipment, and relates to the technical field of image analysis. In order to solve the problem that automatic grading of nasal polyp of a chronic sinusitis patient is difficult to realize in the prior art, an endoscopic image set containing different grades of nasal polyp score marking information is constructed based on nasal endoscopic image data of the patient, and a preset target detection model is trained by using the image set, so that the classification of the nasal polyp of the chronic sinusitis patient is realized. Therefore, the preset target detection model can directly learn and internalize the international standard of nasal polyp grade scoring, and then the preset target detection model can stably learn the nasal endoscope characteristics covering each scoring grade through the full-process training of data enhancement, cross validation and hyper-parameter tuning, so that the accuracy of the nasal endoscopy is improved. And the output nasal polyp grade score has both automation and accuracy, so that the core technical bottleneck of automatic nasal polyp grading under the endoscope is solved.

The invention discloses an application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating eosinophilic chronic sinusitis with nasal polyp. The pharmaceutical preparation is composed of an effective amount of a CGRP receptor small molecule antagonist and pharmaceutically acceptable auxiliary materials, the dosage form is nasal spray / nose drop / irrigation, and the pharmaceutical preparation is simple and convenient in administration route, easy to operate and convenient for patients to use. According to the invention, by inhibiting CGRP-mediated mast cell activation, eosinophilic granulocyte inflammation is significantly relieved, and especially, the traditional Chinese medicine composition has a definite treatment advantage on eosinophilic granulocyte nasal polyp; and compared with a biological agent of a targeted type 2 cytokine, the small molecule compound is safer, simpler and more convenient to obtain, the treatment cost of a patient can be remarkably reduced, and a new efficient and economic choice is provided for nasal polyp treatment.

This invention discloses a method for constructing a sinusitis regulation analysis model based on nasal polyp cell inhibition data, belonging to the field of CRSwNP disease analysis technology. The method includes the following steps: collecting Lund-Kennedy scores and corresponding nasal polyp cell inhibition data from CRSwNP patients to obtain raw sample data; screening the raw sample data to remove unqualified raw sample data from CRSwNP patients to obtain standard sample data; performing index preprocessing based on the standard sample data and obtaining the optimal lag order to obtain reference sample data; constructing an LK analysis prediction model based on the reference sample data and analyzing and predicting the Lund-Kennedy scores of CRSwNP patients. This invention addresses the problem that existing CRSwNP disease analysis technologies cannot provide clinicians with objective and reliable analytical and predictive tools when analyzing and predicting the Lund-Kennedy scores of CRSwNP patients, thus failing to help clinicians reliably predict the disease progression of CRSwNP patients during treatment.

An IL33 antagonist, alone or in combination with an IL-4R antagonist, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyp in a subject having one or more risk alleles in the intron IL1RL1 variant rs1420101, in the IL33 variant rs1342326, both, or in variants of their linkage imbalance.